Faron Pharmaceuticals (UK) Insiders
| FARN Stock | 170.00 2.50 1.49% |
Faron Pharmaceuticals employs about 34 people. The company is managed by 9 executives with a total tenure of roughly 80 years, averaging almost 8.0 years of service per executive, having 3.78 employees per reported executive. Breaking down Faron Pharmaceuticals' management performance can provide insight into the firm performance.
| Juhana Heinonen Executive Chief Officer |
| Birge MD Executive Interim Officer |
Faron |
Faron Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.7) % which means that it has lost $0.7 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (39.615) %, meaning that it generated substantial loss on money invested by shareholders. Faron Pharmaceuticals' management efficiency ratios could be used to measure how well Faron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Faron Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 2.5 M in 2024, whereas Intangible Assets are likely to drop slightly above 691.5 K in 2024.Common Stock Shares Outstanding is likely to drop to about 40.5 K in 2024. Net Loss is likely to gain to about (24.6 M) in 2024
Faron Pharmaceuticals Workforce Comparison
Faron Pharmaceuticals Oy is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1.22 Million. Faron Pharmaceuticals adds roughly 34.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Faron Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Faron Pharmaceuticals Price Series Summation is a cross summation of Faron Pharmaceuticals price series and its benchmark/peer.
Faron Pharmaceuticals Notable Stakeholders
A Faron Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Faron Pharmaceuticals often face trade-offs trying to please all of them. Faron Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Faron Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Markku Jalkanen | Founder Director | Profile | |
| Juhana Heinonen | Chief Officer | Profile | |
| Birge MD | Interim Officer | Profile | |
| Vesa LLM | General Counsel | Profile | |
| MD MSc | Chief Officer | Profile | |
| Jennifer SmithParker | Head Communications | Profile | |
| Maija Hollmen | Chief Officer | Profile | |
| Petri MD | Chief Officer | Profile | |
| MSc MSc | Interim Officer | Profile |
About Faron Pharmaceuticals Management Performance
The success or failure of an entity such as Faron Pharmaceuticals often depends on how effective the management is. Faron Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Faron management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Faron management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Faron Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.
Please note, the imprecision that can be found in Faron Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Faron Pharmaceuticals Oy. Check Faron Pharmaceuticals' Beneish M Score to see the likelihood of Faron Pharmaceuticals' management manipulating its earnings.
Faron Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Faron Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Faron Pharmaceuticals within its industry.Faron Pharmaceuticals Manpower Efficiency
Return on Faron Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 910.1K | |
| Net Loss Per Executive | 3.4M |
Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.